fbpx

molecules of the month

BMS-986144

pan-genotype HCV NS3/4A protease inhibitor

proj. oral QD dosing, well-tolerated in rodent

deuteration reduced CYP TDI

J. Med. Chem., Nov. 23, 2020

Bristol-Myers Squibb, NJ + MA + CT + IN

BMS-986144
1 min read

Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: